Sana Biotechnology (NASDAQ: SANA) EVP files initial ownership report
Rhea-AI Filing Summary
Sana Biotechnology, Inc. executive vice president and chief scientific officer Dhavalkumar Dhirajlal Patel filed an initial ownership report showing his equity interests in the company. The filing lists stock options to purchase 515,000, 375,000, and 506,250 shares of common stock at exercise prices of $5.84, $2.55, and $3.41 per share, with expirations in 2034, 2035, and 2036. It also discloses restricted stock units covering 375,000, 62,500, and 112,500 shares, each RSU representing a contingent right to one share of common stock, along with 99,510 shares of common stock held directly. Footnotes describe standard time-based vesting schedules that require continuous service to Sana.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
PATEL DHAVALKUMAR DHIRAJLAL
Role
EVP, Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 1,396,250 shares (Direct);
Restricted Stock Units — 550,000 shares (Direct);
Common Stock — 99,510 shares (Direct)
Footnotes (7)
- F1. The option vested as to 25% of the shares underlying the option on August 26, 2025 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana Biotechnology, Inc. ("Sana") as an employee, consultant, director or officer of Sana through each such date.
- F2. The option vested as to 25% of the shares underlying the option on March 6, 2026 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
- F3. The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
- F4. Each restricted stock unit represents a contingent right to receive one share of Sana common stock.
- F5. The award vested as to 25% of the restricted stock units on August 26, 2025 and the remaining restricted stock units will vest in three equal installments on each of August 26, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
- F6. The award vested as to 25% of the restricted stock units on March 6, 2026 and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
- F7. The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Sana (SANA) Form 3 filing by EVP Dhavalkumar Patel show?
The Form 3 shows EVP and chief scientific officer Dhavalkumar Patel’s existing equity interests in Sana Biotechnology, including stock options, restricted stock units, and directly held common shares, as he becomes a reportable officer under SEC rules.
How many Sana (SANA) stock options does EVP Dhavalkumar Patel report on Form 3?
The filing lists stock options tied to 515,000, 375,000, and 506,250 shares of Sana common stock, with exercise prices of $5.84, $2.55, and $3.41 per share and expirations in 2034, 2035, and 2036, respectively.
What restricted stock units does Sana (SANA) report for EVP Dhavalkumar Patel?
The Form 3 discloses restricted stock units covering 375,000, 62,500, and 112,500 shares of common stock. Each unit represents a contingent right to receive one share, subject to time-based vesting and continued service conditions described in the footnotes.
What are the vesting terms for Dhavalkumar Patel’s Sana (SANA) stock options and RSUs?
Footnotes state that stock options and restricted stock units generally vest 25% on an initial date, with the remainder vesting in equal monthly or annual installments. Vesting continues only if Patel maintains continuous service to Sana as an employee, consultant, director, or officer.
Does the Sana (SANA) Form 3 indicate any recent stock purchases or sales by EVP Patel?
No purchases or sales are identified. The entries are labeled as holdings, and the transaction summary shows no buy or sell transactions. The Form 3 simply establishes Patel’s existing equity positions as he becomes subject to insider reporting requirements.